Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;19(5):2006-2013.
doi: 10.1002/alz.12846. Epub 2022 Nov 23.

A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting

Ingrid S van Maurik  1   2   3   4 , Hana M Broulikova  5 , Arenda Mank  1   2   3   4 , Els D Bakker  1   2 , Arno de Wilde  1   2   6 , Femke H Bouwman  1   2 , Andrew W Stephens  7 , Bart N M van Berckel  8 , Philip Scheltens  1   2   6 , Wiesje M van der Flier  1   2   3   4
Affiliations

A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting

Ingrid S van Maurik et al. Alzheimers Dement. 2023 May.

Abstract

Introduction: We aim to study the effect of a more precise diagnosis, by means of amyloid positron emission tomography (PET), on institutionalization, mortality, and health-care costs.

Methods: Between October 27, 2014 and December 31, 2016, we offered amyloid PET to all patients as part of their diagnostic work-up. Patients who accepted to undergo amyloid PET (n = 449) were propensity score matched with patients without amyloid PET (n = 571, i.e., no PET). Matched groups (both n = 444) were compared on rate of institutionalization, mortality, and health-care costs in the years after diagnosis.

Results: Amyloid PET patients had a lower risk of institutionalization (10% [n = 45] vs. 21% [n = 92]; hazard ratio [HR] = 0.48 [0.33-0.70]) and mortality rate (11% [n = 49] vs. 18% [n = 81]; HR = 0.51 [0.36-0.73]) and lower health-care costs in the years after diagnosis compared to matched no-PET patients (β = -4573.49 [-6524.76 to -2523.74], P-value < 0.001).

Discussion: A more precise diagnosis in tertiary memory clinic patients positively influenced the endpoints of institutionalization, death, and health-care costs.

Keywords: Alzheimer's disease; amyloid positron emission tomography; clinical utility; health-care costs; institutionalization; mortality; precise diagnosis.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Lesman-Segev OH, La Joie R, Iaccarino L, et al. Diagnostic accuracy of amyloid versus (18) F-Fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia. Ann Neurol. 2021;89(2):389-401.
    1. Kolanko MA, Win Z, Loreto F, et al. Amyloid PET imaging in clinical practice. Pract Neurol. 2020;20(6):451-462.
    1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319.
    1. Chiotis K, Saint-Aubert L, Boccardi M, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214-227.
    1. de Wilde A, van der Flier WM, Pelkmans W, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062-1070.

Publication types

LinkOut - more resources